Kura Oncology launches clinical study for farnesyl transferase inhibitor combination therapy

Kura Oncology launches clinical study for farnesyl transferase inhibitor combination therapy
Kura Oncology starts FIT-001 trial

Kura Oncology has begun actively enrolling adults with advanced clear cell renal cell carcinoma for its FIT-001 Phase 1 clinical trial.

The Phase 1b portion of the trial will evaluate an investigational farnesyl transferase inhibitor used alongside cabozantinib. The company is encouraging patient and stakeholder participation as it advances development of this novel therapeutic approach.

Kura Oncology recently hosted an investor webcast to discuss the launch of Caspian Therapeutics and present preclinical data on KO-7246, according to a previous update (link). The company has also partnered with Caspian Therapeutics to present new preclinical diabetes findings on a next generation menin inhibitor at EASD (link). These activities reflect Kura’s ongoing pipeline development alongside its new clinical strategy.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.